Advertisement

Topics

Latest Women's Health NewsRSS

09:24 EDT 25th September 2017 | BioPortfolio

Prenatal Health Coach Releases Holistic Guide to Pregnancy, Motherhood

Kristy S. Rodriguez delivers gentle, self-love-focused approach to becoming a mom VIENNA, Va. (PRWEB) September 25, 2017 A prenatal health coach and prenatal yoga teacher has released her simple, self-care-focused guide to pregnancy and parenthood for women who are planning pregnancy, women who are pregnant and moms of babies and young children. In “Pure Nurture,” Kristy S. Rodriguez presents...

Global and Regional Prostate Cancer Diagnostics Market Research Report 2017 [Report Updated: 18092017] Prices from USD $3500

SummaryThe prostate is a walnutsized gland located behind the base of a man's penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but...

Global and Regional Circulating Tumor Cells Market Research Report 2017 [Report Updated: 14092017] Prices from USD $3500

SummaryThis report mainly covers Circulating Tumor Cells products, by types CTC enrichment, CTC detection and CTC analysis, by applications Prostate Cancer, Breast Cancer, Colorectal Cancer Diagnosis and Treatment and Others.Market Segment as follows:By Region AsiaPacific North America Europe South America Middle East AfricaBy Type CTC enrichment CTC detection CTC analysis...

Global Erlotinib Hydrochloride Market Data Survey Report 2025 [Report Updated: 07092017] Prices from USD $1500

SummaryErlotinib Hydrochloride is an anticancer drug from protein kinase inhibitors pharmacological group. This medication is used for the treatment of nonsmall cell lung cancer NSCLC, locally advanced, unresectable or metastatic pancreatic cancer, and several other types of cancer. It is usually given after other cancer medicines have been tried without success. Erlotinib acts on the epidermal gr...

Presage Biosciences Awarded Debut Grant from the Mark Foundation for Cancer Research to Support Immuno-Oncology Applications of CIVO™, an Intratumoral Microdosing Platform

Presage Biosciences, an oncology company commercializing CIVO™, a novel drug development platform to assess drugs and combinations directly in-patient tumors, and The Mark Foundation for Cancer Research, an emerging cancer philanthropy, today announced the Foundation’s first-ever award. The grant is aimed at advancing Presage’s next generation of int...

TherapeuticsMD Announces Move to Nasdaq Global Select Market

TherapeuticsMD, Inc. (NYSE American:TXMD), an innovative women’s healthcare company, today announced that it will voluntarily move its stock exchange listing to the Nasdaq Global Select Market from the NYSE American LLC. The Company expects its common stock will begin trading on the Nasdaq Global Select Market on October 9, 2017 and its shares will conti...

Hyundai Hope On Wheels To Award $250,000 Research Grant To UR Medicine's Golisano Children's Hospital Of Rochester, NY, In Honor Of National Childhood Cancer Awareness Month

ROCHESTER, N.Y., Sept. 25, 2017 /PRNewswire/ -- On Wednesday, September 27, 2017, Hyundai Hope On Wheels® will present UR Medicine's Golisano Children's Hospital with a $250,000 Hyundai Scholar Hope Grant. The grant funds will support the research of principal investigator Craig Mullen, M.D., Ph.D., the chief of Golisano Children's Hospital's Pediatric Hematology/Oncology Division. This...

ViewRay Launches Clinical Trial Following Compelling Early Pancreatic Cancer Data with MRIdian System

CLEVELAND, Sept. 25, 2017 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today the launch of a multi-center prospective clinical trial for locally advanced unresectable pancreatic cancer using MRIdian, the world's first and only FDA-cleared MRI-guided radiation therapy system. This study is the first initiative of ViewRay's Clinical Cooperative Think Tank (C2T2), a group of MRIdian cl...

Cannabics Pharmaceuticals Files National Phase Applications for Its System and Method for High Throughput Screening of Cancer Cells

TEL AVIV, Israel, September 25, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) today announced it has filed national phase patent applications for its 'System and Method for High Throughput Screening of Cancer Cells' in the United States, Europe, China, India, Brazil, Canada and Australia.

With the Nobel Prizes around the corner, it’s crystal ball time

The scientists who pioneered immunotherapy and other cancer advances are among the favorites for this year's Nobel Prizes, which will be announced the first week of October.

Infinity Pharmaceuticals and Bristol-Myers Squibb Expand Clinical Collaboration Evaluating IPI-549 in Combination with Opdivo (Nivolumab)

CAMBRIDGE, Mass., Sept. 25, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has expanded its existing clinical collaboration with Bristol-Myers Squibb evaluating IPI-549 in combination with Opdivo® to include patients with triple negative breast cancer (TNBC) who have not been previously exposed to anti-PD-1 or anti-PD-L1 therapy. IPI-549 is an...

TapImmune Appoints Peter Hoang as President and Chief Executive Officer

JACKSONVILLE, Fla., Sept. 25, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women's cancers, today announced that the Company has appointed Peter L. Hoang as its President and Chief Executive Officer. Dr. Glynn Wilson, who was recently re-appointed as Chairman by the Board, will now serve i...

Ocugen Announces FDA Acceptance of Investigational New Drug Application for OCU310 (brimonidine/steroid combination therapy) and Initiates Proof of Concept Study for Treatment of Dry Eye Disease

MALVERN, Pa., Sept. 25, 2017 /PRNewswire/ -- Ocugen, Inc., a clinical stage biopharmaceutical company developing novel treatments for sight-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application for OCU310 (brimonidine/steroid combination therapy), a topical formulation for the treatment of dry eye disease...

Sciton Launches Project Pink diVa Campaign with Young Survival Coalition Sponsorship

PALO ALTO, Calif., Sept 25, 2017 /PRNewswire/ -- Sciton, Inc. is pleased to announce a partnership between its Women's Health Group division and the Young Survival Coalition. The Women's Health Group, as part of Sciton's "Because Results Matter" mission and making a difference in the quality of people's lives, is undertaking a philanthropic initiative to raise awareness about women's vaginal ...

eTheRNA immunotherapies Awarded €1 Million Grant From Flanders Innovation & Entrepreneurship to Further Upgrade its State-of-the-art Production Process for TriMix mRNA Immunotherapies

NIEL, Belgium, September 25, 2017 /PRNewswire/ -- eTheRNA immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its unique TriMix platform, announces it has been awarded a €1 million industrial R&D Projects Grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used by eTheRNA to further develop and optimize its state-of-the-a...

Online screening for depression: Here’s what one physician thinks about it

Inquisitive reader Amy asked me if I had any opinions about online screening for depression. The British Medical Journal recently published a debate on this issue. What an excellent question, Amy! I read the opposing arguments, and these are my thoughts: First, I see two different issues. The first is whether the 9-question Patient Health Questionnaire […]

Majority of women do not know early signs of breast cancer, finds global survey by Avon

LONDON, Sept. 25, 2017 /PRNewswire/ -- Only two in five people (42%) are confident about recognising the changes to their breasts that could be a sign of cancer, according to a new survey of 19,000 respondents by Avon Products, Inc., the world's leading social selling company[i]. The findings also show there is a knowledge gap amongst women globally about what the symptoms are for breast cancer an...

Interpace Diagnostics Announces Expansion into New Clinical Area with Launch of Molecular Lung Cancer Test

PARSIPPANY, N.J., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today the launch of a new lung cancer test, MVPdX™, that differentiates t...

Presage Biosciences Awarded Debut Grant From The Mark Foundation For Cancer Research To Support Immuno-Oncology Applications Of CIVO, An Intratumoral Microdosing Platform

  Life Sciences Jobs   ...

Study at urban cancer center finds 75 percent of its depressed patients were previously undiagnosed

SAN DIEGO, Sept. 24, 2017 /PRNewswire-USNewswire/ -- A new study of patients at an urban cancer center points to a potentially serious problem that may limit the impact of clinical cancer care—undiagnosed depression. Among the 40 percent of patients at the center who were diagnosed with depression, three in four had not previously been told they were depressed. Female patients and disabled ...

International trial confirms safety, effectiveness of high-dose brachytherapy plus pelvic radiation for cervical cancer

SAN DIEGO, Sept. 24, 2017 /PRNewswire-USNewswire/ -- Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy, or internal radiation therapy, for managing locally advanced cervical cancer. Tumor control was significantly better following four fractions of 7 Gray (Gy) each than following two, 9-Gy fractions of high-dose-rate (HDR) brach...

Retinoic Acid Receptor Beta RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB Pipeline Review, H2 2017 [Report Updated: 19092017] Prices from USD $3500

Retinoic Acid Receptor Beta RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB Pipeline Review, H2 2017SummaryRetinoic Acid Receptor Beta RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB Retinoic acid receptor beta RARB is a nuclear receptor that is encoded by the RAR...

Prostate Conditions Education Council Opposes U.S. Preventative Services Task Force Recommendation

DENVER, Oct. 10, 2011 /PRNewswire-USNewswire/ -- The Prostate Conditions Education Council (PCEC) – a national organization committed to men's health and a leader in prostate cancer screening – today announced it strongly opposes the newly released recommendations from the U.S. Preventative Services Task Force (USPSTF). The draft guidance recommends against prostate-specific antigen (P...

Global Cancer Vaccine Partnering 20102017: Deal trends, players, financials and forecasts [Report Updated: 01092017] Prices from USD $2995

The Global Cancer Vaccine Partnering 20102017 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer vaccine partnering dealsDisclosed headlines, upfronts, milestones and royalties by stage of developmentCancer vaccine partnering contract documentsTop cancer vaccine deals by value T...

Qfix® Launches New Radiotherapy Positioning Technology for the More Precise Treatment of Breast Cancer

AVONDALE, Pa., Sept. 23, 2017 /PRNewswire/ -- Today, Qfix announced the release of the first-in-its-class kVue™ Access 360™ G2 and Access™ Prone G2 positioning devices that promise to improve prone breast cancer treatment by significantly reducing radiation dose to healthy tissue while improving patient comfort and reproducible positioning. By allowing breast tissue to fall away from th...

Quick Search
Advertisement
 

review and buy Women's Health market research data and corporate reports here